Biology

Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.

Related Articles

Rebound vertebral and non-vertebral fractures during denosumab interruption in a postmenopausal woman.

Clin Endocrinol (Oxf). 2018 Sep 30;:

Authors: De Sousa SM, Jesudason D

Abstract
Denosumab is a monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) with potent antiresorptive activity. In Australia, it is available alongside bisphosphonates as a first-line osteoporosis therapy on the Pharmaceutical Benefits Scheme (PBS). Denosumab is often preferred because of ease of administration, tolerability and safety/efficacy in patients with restricted renal function. Some dentists and clinicians may find denosumab attractive because of its reversibility, possibly allowing for dental procedures between injections or after a short interruption of therapy with a theoretically smaller risk of osteonecrosis of the jaw. This article is protected by copyright. All rights reserved.

PMID: 30269340 [PubMed – as supplied by publisher]

Source link




Related posts

Scientists discover the structure of cancer molecule

Newsemia

Changes of gene expression but not cytosine methylation are associated with male parental care reflecting behavioural state, social context, and individual flexibility [RESEARCH ARTICLE]

Newsemia

Large-scale death of retinal astrocytes during normal development is non-apoptotic and implemented by microglia

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy